ClinicalTrials.gg
CompletedNCT07922096Updated Nov 6, 2026

A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors

A Phase 1 interventional study of SMP-656 Injection in HER2-Expressing Advanced Solid Tumors, HER2-Mutated Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Chengdu SciMount Pharmatech Co., Ltd.. Completed at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Chengdu SciMount Pharmatech Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Feb 2024, registered Nov 2026).
Updated Nov 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of SMP-656 in subjects with locally advanced/metastatic HER2 expressing or HER2-mutated solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, non-small cell lung cancer, gynecologic, gastrointestinal and other solid tumors.

A total of 35 participants were enrolled between February 2024 and April 2026. The trial has been completed.

Read the detailed description

This was a first-in-human, open-label, multicenter Phase I study to assess the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of SMP-656, in patients with locally advanced/metastatic HER2 expressing or HER2-mutated solid tumors.

The trial enrolled 35 participants at five sites in China.

Dose-escalation stage: SMP-656 was administered by intravenous infusion once every 3 weeks (Q3W; each 21-day period was one treatment cycle) using a classical 3+3 design.

Dose-expansion stage: participants were enrolled and treated Q3W at the dose level(s) selected from dose escalation.

02

Conditions studied

  • HER2-Expressing Advanced Solid Tumors
  • HER2-Mutated Advanced Solid Tumors
  • Metastatic Solid Tumors

Keywords

  • SMP-656
  • Phase I
  • Advanced Solid Tumors
03

In context

Lead sponsor

Chengdu SciMount Pharmatech Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this clinical trial, understand and comply with study procedures, and provide written voluntarily.
  2. Male or female; aged >= 18 years at the time of signing the informed consent form.
  3. Expected survival >= 12 weeks.
  4. or cytologically confirmed -expressing or HER2-mutated advanced solid tumors .
  5. In the dose-expansion stage, patients must additionally meet the requirements of one of the following cohorts: (1) HER2-positive or HER2-low breast cancer; (2) HER2-mutated or -amplified NSCLC ; (3) Other HER2-positive or HER2-mutated solid tumors.
  6. Have at least 1 measurable target lesion per Version 1.1 (RECIST v1.1).
  7. (ECOG) performance status 0-1.
  8. Adequate bone marrow, hepatic, renal and coagulation function based on laboratory tests performed within 7 days before the first dose.
  9. Women of (WOCBP) must agree to use highly effective or maintain abstinence from the time of informed consent signature through 7 months after the last administration of the product; serum pregnancy testing performed within 7 days before the first dose must be negative. Male patients of childbearing potential must agree to use highly effective contraception and not to donate sperm during the same period.

Exclusion criteria

Exclusion Criteria:

  1. Insufficient washout of prior antitumor therapy before the first dose: chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives (whichever is shorter); antibody therapy within 3 weeks; hormonal therapy within 2 weeks; antitumor Chinese patent medicine within 2 weeks; palliative radiotherapy within 2 weeks; radical radiotherapy within 4 weeks; nitrosoureas or mitomycin within 6 weeks; major surgery within 28 days; any other antitumor agent within 28 days.
  2. Have received eribulin or an eribulin-containing ADC in .
  3. Known history of severe to inetetamab, SMP-656 or any of their .
  4. Prior anti-tumor treatment-related toxicities (alopecia excluded) that remain at Grade > 1 or have not recovered to baseline, except adverse events deemed by the Investigator not to pose a safety risk.
  5. Grade >= 2 peripheral neuropathy, or prior history of Grade >= 3 neurotoxicity/peripheral neuropathy, or permanent discontinuation of previous antitumor treatment due to neurotoxicity or peripheral neuropathy.
  6. Uncontrollable pleural effusion, pericardial effusion or ascites.
  7. Diabetes mellitus that remains uncontrolled despite optimal supportive care.
  8. Previous, current or suspected interstitial lung disease (ILD), drug-induced ILD, or active pneumonia identified at screening, or radiation pneumonitis, or other severe pulmonary disorders impairing respiratory function which, in the Investigator's judgment, may interfere with the detection or management of investigational product-related pulmonary toxicity.
  9. Primary central nervous system (CNS) tumors, meningeal , or active that have failed local treatment.
  10. Any other (other than the study tumor type) diagnosed within 5 years before the first dose, except curatively treated localized malignancies such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, papillary thyroid carcinoma or ductal carcinoma in situ of the breast.
  11. Pre-existing disease requiring systemic treatment (excluding replacement therapy for thyroid, adrenal or pituitary insufficiency).
  12. History of stem cell transplantation or solid organ transplantation, or planned allogeneic stem cell transplantation or solid organ transplantation during the study.
  13. Current drug-induced liver injury, autoimmune liver disease , persistent extrahepatic obstruction caused by gallstones, cirrhosis or portal hypertension.
  14. Clinically significant history of cardiovascular disease,.
  15. Active infection, including clinically uncontrolled active infectious disease such as acute pneumonia or persistent fever of unknown origin within 7 days before the first dose.
  16. Pregnancy or lactation.
  17. Any concurrent uncontrolled disease that, in the Investigator's judgment
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part 1: Dose-escalation six doses levels have been selected for evaluation

    SMP-656 administered intravenously once every 3 weeks (Q3W)

    Drug: SMP-656 Injection

Interventions

  • DrugSMP-656 Injection

    SMP-656 was supplied as a 50 mg/vial injection for intravenous infusion and given Q3W at 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 mg/kg during dose escalation and at the selected dose level(s) during dose expansion. Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death or trial termination.

    Also known as: SMP-656

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT)

    Number and percentage of participants who experienced a protocol-defined DLT during the 21-day DLT observation period after the first SMP-656 infusion, graded according to NCI CTCAE v5.0 (hematologic, hepatic and non-hematologic/non-hepatic toxicities).

    Time frame: 21 days after the first dose of SMP-656

  2. Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D)

    The MTD and/or RP2D of SMP-656 determined from the integrated analysis of DLT, safety, pharmacokinetic and preliminary antitumor activity data across the five dose levels evaluated (0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg).

    Time frame: Through study completion, up to 27 months from first dose

Secondary outcomes

  1. Objective Response Rate (ORR) Assessed by Investigators

    ORR is the percentage of evaluable patients with a confirmed investigator-assessed response of complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 27 months)

  2. Duration of Response (DOR)

    DOR is the time from the date of first documented confirmed objective response (CR or PR per RECIST v1.1) until the date of disease progression or death.

    Time frame: From first confirmed objective response (CR/PR) up to 27 months from first dose

  3. Progression-Free Survival (PFS)

    PFS is the time from the date of first dose until the date of objective radiographic disease progression or death (by any cause in the absence of progression).

    Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 27 months)

  4. 1-Year Overall Survival Rate

    Proportion of participants alive 1 year after the first dose of SMP-656.

    Time frame: 1 year after the first dose

  5. Area Under the Concentration Versus Time Curve (AUC) of Serum SMP-656 Following First Dose

    The serum PK parameters of SMP-656 and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.

    Time frame: Post first dose up to 2 years

  6. Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum SMP-656 Following First Dose

    The serum PK parameters Maximum (peak) Observed serum concentration of SMP-656 and its analytes were estimated using standard non-compartmental method.

    Time frame: Post first dose up to 2 years

  7. Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum SMP-656 Following First Dose

    The serum PK parameters of Time of maximum plasma concentration (Tmax) for SMP-656 and its analytes were estimated using standard non-compartmental methods.

    Time frame: Post first dose up to 2 years

  8. Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of SerumSMP-656 Following First Dose

    The serum PK parameters of Terminal elimination half-life forSMP-656 and its analytes was estimated using standard non-compartmental methods.

    Time frame: Post first dose up to 2 years

  9. Overview of Treatment-emergent Adverse Events

    Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Event

    Time frame: Baseline up to 28 days after the last dose of study drug

07

Study locations

5 sites
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Apr 2026, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2026
First posted
Nov 6, 2026
StartActual
Feb 1, 2024
Primary completionActual
Apr 30, 2026
CompletionActual
Apr 30, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07922096
Lead sponsor
Chengdu SciMount Pharmatech Co., Ltd.
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Feb 1, 2024
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Nov 6, 2026

Study contacts

Jian Zhang, MD
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion